argenx to acquire Unnatural Products for $1.15bn
argenx already holds a minority stake in UNP and will acquire all remaining shares
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Veradermics announces phase 3 results for oral minoxidil for hair loss
If approved, it would be the only FDA-approved, oral, non-hormonal treatment for pattern hair loss in both male and female patients
argenx to acquire Unnatural Products for $1.15bn
argenx already holds a minority stake in UNP and will acquire all remaining shares
Karyopharm announces planned merger with Ayrmid amid Chapter 11 bankruptcy filing
The merger is not final and other companies will be able to bid for Karyopharm’s assets
AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences
The new site will expand research capabilities across immunology, neuroscience and oncology
MAD World Summit 2026 secures official accreditation from The CPD Group
MAD World Summit takes place in London on 26 November at Convene, 155 Bishopsgate
Latest content
Agentic commercial: AI redefines field, digital and content for precision engagement
Continuous engagement depends on a steady stream of timely, compliant content
Read More
The invisible influencer: the new information layer between doctors and scientific evidence
When priority scientific questions are being answered, how visible, accurate and useful is our evidence?
Read More
The future of science communication is already on social
We need to make scientific information easier to find and support more evidence-based voices online
Read More
Trust doesn’t travel through channels. It travels through people
Influence rarely happens in a single post. Trust is built through repeated, credible interactions over time
Read More
Intelligence
The next phase of oral GLP-1s
Three waves of innovation pharma leaders should watch
Read More
A rare opportunity – incentivising development of new treatments for rare diseases
Investment in rare disease biotechs has increased since the FDA’s Priority Review Voucher scheme was renewed
Read More
Using the power of social media to break down obstacles preventing improved patient engagement
Connecting with patients and HCPs through social media channels needs care and consistency
Read More
Who’s steering? Why pharma needs humans at the helm of AI
Understanding how AI decisions are made, who owns the outcomes and how accountability travels across partners and platforms
Read More
The impact of AI and digital health on chronic diseases
Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, but what impact is this having on the pharma industry?
Read More
Regulatory complexity: the challenges of navigating the new normal
How functional service provider models are helping pharma adapt to regulatory uncertainty
Read More
Blogs
Latest
Medscape Oncology Lights the Night to Advance Blood Cancer Care
November 10, 2026 | Medscape Education|Blood Cancer United, Caregiver Central Sponsor, Hematology Education, Light the Night
MERCER COUNTY, NJ — Recognizing that clinical excellence and patient experience are inseparable, Medscape Oncology served as the official Caregiver Central Sponsor in support of …
Genesis Research Group launches Keystone IEGP platform at ISPOR Europe 2026
November 10, 2026 | Genesis Research Group|AI, HEOR, Market Access, RWE, evidence generation, evidence generation planning platform, evidence planning, evidence strategy, iegp, technology
Genesis Research Group (Genesis) launches Keystone, its modular platform for Integrated Evidence Generation Planning (IEGP), at ISPOR Europe 2026.
Petauri Expands Global Medical Communications Capabilities With Acquisition of Emotive
November 10, 2026 | Emotive—Powered by Petauri|
Acquisition strengthens Petauri’s medical communications collective, Petauri Advance, with expanded global scale and deep scientific, strategic, and creative expertise.
Reaching New Heights in Liver Care: The Power of Strategic Advocacy in Liver Health
November 9, 2026 | Medscape Education|AASLD, Fatty Liver Alliance, Liver Health, MASH, Medscape Event, patient advocacy
“The view from the top is always better with the people who helped us get there.”
Inizio appoints Oisín Ó Gógáin as Chief People Officer
November 3, 2026 | Inizio|Pharma, healthcare
Inizio has appointed Oisín Ó Gógáin as Chief People Officer.
Key takeaways from MedAffairs Transformation: creating a high-value medical affairs organization in the age of AI
November 9, 2026 | Amiculum|artificial intelligence, medical affairs
What does a high-value medical affairs organization look like in a world of constrained resources, increasingly capable artificial intelligence (AI) and easier access to scientific …
How pharma companies can use AI to scale personalized engagement without increasing complexity
November 3, 2026 | Inizio|AI, Pharma, healthcare
AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI …
Creating the conditions for product launch success in a time of volatility
November 3, 2026 | Inizio|Pharma, Product Launch, healthcare
Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident …
Navigating uncertainty in life sciences
November 3, 2026 | Inizio|Pharma, healthcare
The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for …
Going private: what our year taught me about the patients pharma hasn’t yet spotted
October 26, 2026 | 11 London|
A thought piece on the rise of private healthcare, and why brands should help new kinds of patients and HCPs